AR and cancer: The potential therapeutic use of these agents, including second-generation anti-androgens apalutamide (ARN-509) [12], darolutamide (ODM-201) [13] and enzalutamide (MDV3100) [14], has been explored in other AR+ cancers, including AR+ breast cancers.